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http://dx.doi.org/10.1016/j.kjms.201Abstract This study assessed the relationship between low-density lipoprotein cholesterol
(LDL-C) levels on admission and the incidence of major adverse cardiovascular events (MACE)
in patients with acute ST-segment-elevation myocardial infarction (ASTEMI). Patients with AS-
TEMI who had a lipid profile tested within 24 hours of symptom onset were enrolled. They were
stratified into high and low LDL-C groups according to whether their LDL-C was above (nZ 501)
or below (n Z 575) the median level, respectively. The incidence of MACE, cardiovascular
death, non-fatal MI, revascularization, and stroke was compared between the groups at 1
month, 6 months, and 1 year. Survival analysis and Cox proportional hazard analysis were per-
formed. In-hospital use of beta blockers was better in the high than in the low LDL-C group
(76.6% vs. 69.7%, p Z 0.01). Statin use was significantly higher in the high than in the low
LDL-C group during follow-up (86.8% vs. 80.0%, p Z 0.003 at1 month; 71.6% vs. 62.4%,
p Z 0.002 at 6 months; 67.8% vs. 61.2%, p Z 0.03 at 1 year). The incidence of MACE on
follow-up at 1 month was higher in the low than in the high LDL-C group (12.0% vs. 8.1%,
p Z 0.04). At 1 year, survival was not significantly different between the groups. Cox propor-
tional hazards analysis indicated that the incidence of MACE was significantly associated with
hypertension, current smoking, high-density lipoprotein cholesterol (HDL-C), in-hospital use of
beta blockers, and statin use on follow-up (p < 0.01). LDL-C levels on admission in patients
with ASTEMI had no significant effect on the 6-month and 1-year incidence of MACE, but the
incidence of MACE was significantly higher in the low LDL-C group at 1 month. It would be rele-
vant to further investigate the HDL-C level on admission, in-hospital use of beta blockers, and
statin use during follow-up in relation to MACE.
Copyright ª 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
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clinical data were collected, including age, gender, body
2It is well known that elevated low-density lipoprotein
cholesterol (LDL-C) is a major risk factor for cardiovascular
disease [1]. A number of randomized controlled clinical
trials, including 4S [2], CARE [3], LIPID [4], WOSCOP [5], and
AFCAPS/TexCAPS [6], confirmed that a reduction in LDL-C
by statins reduced the risk of cardiovascular events in
patients with coronary heart disease and cardiovascular risk
factors. It appears that lower LDL-C levels are associated
with better prognosis. In practice, many patients still have
a high risk of major adverse cardiovascular events (MACE)
despite aggressive statin therapy that lowers LDL-C [7e9]
and contributes to achievement of the LDL-C target level
[2e5]. Mouaz et al. found that a lower 3-year survival in
patients with non-ST-segment-elevation myocardial
infarction (NSTEMI) was associated with lower LDL-C on
admission [10]. Hypocholesterolemia is associated with
poorer clinical outcomes in patients with high cardiovas-
cular risk and coronary heart disease, and in patients with
some other diseases, such as chronic kidney disease and
malignancy [11e18]. Low LDL-C on admission to hospital
and LDL-C-lowering with statins may not have similar
effects in reducing MACE. However, few studies have
assessed the impact of LDL-C levels on admission in patients
with acute ST-segment-elevation myocardial infarction
(ASTEMI). In the present study we investigated the clinical
characteristics, in-hospital management, treatment after
discharge, and outcome of patients with ASTEMI.
Methods
Study population
A prospective, multicenter study conducted on patients
with ASTEMI in LiaoNing Province in northeast China
included 1429 consecutive patients who were admitted to
20 hospitals between May 2009 and May 2010. ASTEMI was
defined according to the American College of Cardiology/
American Heart Association ASTEMI criteria [19]. Patients
were enrolled if they had a specific time of symptom onset,
with symptoms including chest pain, dyspnea, and syncope,
and if they were admitted to the hospital and had their lipid
profile measured within 24 hours of symptom onset.
Patients who did not meet these criteria, who were diag-
nosed with NSTEMI, or who had incomplete data were
excluded. Finally, a total of 1076 patients were enrolled.
The protocol was approved by the ethics committee of the
study hospitals, and all patients gave written informed
consent.
Study design
The patients were stratified into two groups according to
their LDL-C level on admission: one group with LDL-C
below the median for all patients, and the other with LDL-
C above the median. Patients received emergency percu-
taneous coronary intervention (PCI) or coronary artery
bypass graft (CABG), thrombolysis, and medical care
according to their conditions and the availability ofservices in the admitting hospital. Basic demographic and
mass index (BMI; kg/m ), smoking history, history of
disease and medication, blood analysis [LDL-C, high-
density lipoprotein cholesterol (HDL-C), total cholesterol
(TC), triglyceride (TG), peak troponin, and creatinine]. In
addition, patient status on admission (cardiogenic shock,
ventricular arrhythmia, and Killip class) and methods of
treatment were determined.
All subjects attended follow-up visits at 1 month, 6
months, and approximately 1 year after hospital discharge.
Information on drug use and the incidence of MACE were
recorded. In the present study, MACE was defined as
cardiovascular death, non-fatal MI, revascularization, or
stroke. The primary endpoint was the rate of 1-year MACE,
and the secondary endpoints were the rate of 1-month and
6-month follow-up MACE.
Statistical analysis
Continuous data are expressed as mean  standard devi-
ation and were analyzed using the Student t test. Cate-
gorical data are expressed as n (%) and were analyzed
using the c2 test or the Fisher exact test. Survival curves
were prepared using the KaplaneMeier method with the
log-rank test. Univariate analysis of age, gender, BMI,
current smoking, diabetes, hypertension, LDL-C, HDL-C,
TC, TG, and other factors was performed to determine the
predictors for MACE. A multiple Cox proportional hazard
model was used to determine associations between
significant factors identified in the univariate analysis and
those identified in the MACE. A p value <0.05 was
considered statistically significant. All analyses were
performed using SPSS version 13.0 (SPSS Inc., Chicago, IL,
USA).Results
The median LDL-C level for all subjects on admission was
2.94 mmol/L; 501 patients had LDL-C >2.94 mmol/L (high
LDL-C group), and 575 patients had LDL-C 2.94 mmol/L
(low LDL-C group). The median follow-up duration was
274.07  135.36 days. During the follow-up period, three
patients died, one of a serious infection, one due to
a traffic accident, and one due to gastrointestinal bleeding.
In addition, 37 patients were lost to follow-up. The follow-
up rate for the high and low LDL-C groups was 96.6% and
96.0%, respectively.
Baseline characteristics
Baseline characteristics are summarized in Table 1. BMI and
the prevalence of diabetes were significantly higher in the
high than in the low LDL-C group (25.30  3.09 vs.
24.77  3.40, p < 0.001 and 21.0% vs. 16.3%, p Z 0.04,
respectively). The proportion of men was significantly
higher in the low than in the high LDL-C group (78.3% vs.
67.5%, p < 0.001). There were no significant differences
with regard to age, history of disease, and modes of
treatment between the groups.
Table 1 Baseline characteristics of the study patients.
Variable Low-density lipoprotein cholesterol p
>2.94 mmol/L 2.94 mmol/L
Patients 501 575
Age (y) 62.07  12.57 63.20  12.01 0.13
Age  65 y 221 (44.1) 269 (46.8) 0.38
Male 338 (67.5) 450 (78.3) <0.001
Body mass index (kg/m2) 25.30  3.09 24.77  3.40 <0.001
Previous angina pectoris 131 (26.1) 166 (28.9) 0.32
Previous myocardial infarction 29 (5.8) 40 (7.0) 0.44
Previous stroke 52 (10.4) 82 (14.3) 0.06
Chronic heart failure 5 (1.0) 4 (0.7) 0.59
Diabetes 105 (21.0) 93 (16.3) 0.04
Medication for control of blood sugara 82 (16.4) 74 (12.9) 0.10
Hypertension 231 (46.1) 254 (44.2) 0.53
Lipid-lowering therapy 17 (3.4) 14 (2.4) 0.35
Chronic renal failure 6 (1.2) 12 (2.1) 0.26
Current smoker 223 (44.5) 266 (46.3) 0.57
Family history of coronary heart disease 102 (20.4) 124 (21.6) 0.63
Previous percutaneous coronary intervention 12 (2.4) 26 (4.5) 0.06
Previous coronary artery bypass grafting 0 0 0.99
Data are presented as n (%) or mean  SD.
a Hypoglycemic medication or insulin therapy.
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findings on admission
The clinical characteristics, treatment, and laboratory
findings on admission are summarized in Table 2. There
were no significant differences in cardiogenic shock and
ventricular arrhythmia on admission, Killip class,
thrombolysis, thrombolytic reperfusion, emergency and
selective PCI, vessel with PCI, CABG, peak troponin, TC,
creatinine, and ejection fraction between the groups.
Levels of HDL-C and TG on admission were significantly
higher in the high than in the low LDL-C group
(1.31  0.41 vs. 1.23  0.39 mmol/L, p Z 0.001 and
2.02  1.58 vs. 1.66  1.49 mmol/L, p < 0.001,
respectively).
Medications
The medications used in the hospital and after 1-month, 6-
month, and approximately 1-year follow-up are summa-
rized in Table 3. Use of aspirin, clopidogrel, statins,
angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers (ACEI/ARB), glycoprotein IIb/IIIa inhib-
itors, and low-molecular-weight heparin in hospital did
not significantly differ between the groups. The in-
hospital use of beta blockers was greater in the high
than in the low LDL-C group (76.6% vs. 69.7%, p Z 0.01).
During follow-up, there were no significant differences in
the use of aspirin, clopidogrel, ACEI/ARB, or beta blockers
between the groups. However, statin use was significantly
higher in the high than in the low LDL-C group during
follow-up (86.8% vs. 80.0%, p Z 0.003 at 1 month; 71.6%
vs. 62.4%, p Z 0.002 at 6 months; 67.8% vs. 61.2%,
p Z 0.03 at 1 year).MACE in hospital and during follow-up
The incidence of MACE in the hospital and during 1-year
follow-up is summarized in Table 4. The incidence of MACE
was significantly higher in the low than in the high LDL-C
group at 1-month follow-up (12.0% vs. 8.1%, p Z 0.04).
The incidence of MACE in the hospital and at 6-month and
1-year follow-up did not significantly differ between the
groups.
Survival curves and Cox proportional hazard
analysis
Survival curves are depicted in Fig. 1. At 1 year, the survival
rate did not significantly differ between the groups.
According to a univariate analysis, the independent predic-
tors of MACE were age, gender, diabetes, hypertension,
current smoking, HDL-C, statin use, and beta blocker use in
hospital (Table 5). A multiple Cox proportional hazard model
was prepared to identify independent predictors of MACE
using factors that were significant in the univariate analysis.
The independent predictors were hypertension [hazard ratio
(HR) 1.517, 95% confidence interval (CI) 1.061e2.170,
pZ 0.022], current smoking (HR 2.440, 95% CI 1.599e3.725,
p< 0.001), HDL-C (HR 0.306, 95% CI 0.173e0.541, p< 0.001),
beta blocker use in hospital (HR 0.66, 95% CI 0.457e0.955,
p Z 0.027), and statin use (HR 0.602, 95% CI 0.423e0.856,
pZ 0.005) (Table 6).
Discussion
Our results demonstrate that LDL-C levels on admission in
patients with ASTEMI were not significantly associated with
the 1-year incidence of MACE. However, the incidence of
Table 2 Clinical characteristics, treatment, and laboratory findings for the study patients.
Variable Low-density lipoprotein cholesterol p
>2.94 mmol/L 2.94 mmol/L
Patients 501 575
Cardiogenic shock on admission 11 (2.2) 21 (3.7) 0.16
Ventricular arrhythmia on admission 51 (10.2) 73 (12.7) 0.20
Killip class 0.21
I 426 (85.0) 468 (81.4)
II 43 (8.6) 65 (11.3)
III 21 (4.2) 21 (3.7)
IV 11 (2.2) 21 (3.7)
Thrombolytic therapya 137 (27.3) 136 (23.7) 0.17
Thrombolytic reperfusionb 118 (23.6) 112 (19.5) 0.10
Urgent PCIc 142 (28.3) 185 (32.2) 0.17
Selective PCId 56 (11.2) 55 (9.6) 0.39
Vessel with PCI 0.58
Left main artery 1 (0.50) 2 (0.8)
Left anterior descending artery 90 (44.8) 125 (50.6)
Left circumflex artery 32 (15.9) 38 (15.4)
Right coronary artery 78 (38.8) 82 (33.2)
Coronary artery bypass grafting 1 (0.2) 0 0.99
Peak troponin (mmol/L) 20.45  39.03 22.37  27.58 0.35
High-density lipoprotein cholesterol (mmol/L) 1.31  0.41 1.23  0.39 0.001
Total cholesterol (mmol/L) 5.69  1.00 5.07  19.1 0.47
Triglyceride (mmol/L) 2.02  1.58 1.66  1.49 <0.001
Creatinine 78.37  35.05 81.06  33.11 0.2
Ejection fraction (%) 50.69  8.15 50.93  8.94 0.64
Data are presented as n (%) or mean  SD.
PCI Z percutaneous coronary intervention.
a The thrombolytic protocol was 1.5 mU urokinase over 30 minutes or an 8-mg bolus of recombinant tissue-type plasminogen activator,
followed by 42 mg over 90 minutes.
b Thrombolytic reperfusion was assessed by standard invasive and non-invasive methods. In the invasive method, angiographic findings
were assessed according to the thrombolysis in myocardial infarction (TIMI) criteria. TIMI grades II or III were defined as successful
reperfusion. The non-invasive methods included (1) rapid ST-segment normalization defined as a fractional change 50% at 2 hours; (2)
rapid relief of chest pain at 2e3 hours after the start of thrombolytic treatment; (3) occurrence of reperfusion arrhythmia; (4) peak time
of creatine kinase-MB/creatine kinase advanced to 14e16 hours after the onset of acute myocardial infarction (AMI). Reperfusion was
considered to have been achieved for patients for whom two items of (1)e(4) applied, unless the two items were (2) and (3). If the start
of thrombolytic treatment was within 6e12 hours after AMI onset, (4) did not apply.
c Intervention in the culprit vessel within 12 hours after the onset of chest pain or other symptoms, without previous (full or
concomitant) thrombolytic or other clot-dissolving therapy.
d Intervention in the culprit vessel within 3e24 hours after thrombolysis therapy.
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LDL-C group at 1-month follow-up. A few epidemiological
studies have shown a relationship between lipid levels and
the incidence of MACE, but these included only patients
undergoing angiography and PCI [10,20]. In China, not all
patients with ASTEMI are able to have emergency PCI
treatment; therefore, our study included all patients
undergoing various treatments that reflect the situation in
the real world. The treatment methods in hospitals did not
significantly differ between the groups.
Some studies have reported that an acute decrease in
LDL-C (usually accompanied by an increase in TG), which
happens over a few days, is associated with a larger MI
[13,14,16]. However, in the present study, TG was signifi-
cantly lower in the low LDL-C group during the first 24
hours, and the size of the MI, according to peak troponin
and left-ventricle ejection fraction, did not significantly
differ between the groups. There were no differencesbetween the groups with regard to Killip classification,
shock, ventricular arrhythmia, and location of the lesion;
therefore, these confounding factors should not have
a bearing on the difference in outcome between the
groups. The study did reveal an association between LDL-C
on admission and 1-month outcome in patients with
ASTEMI.
The incidence of MACE at 1-month follow-up was
significantly higher in the low than in the high LDL-C group.
Al-Mallah et al. observed that low LDL-C on admission was
associated with a decreased 3-year survival in patients with
NSTEMI, but the authors did not provide information on the
drugs used during follow-up [10]. The medications used in
our study at follow-up were fully recorded. Data analysis
revealed that the greatest difference between the groups
during the follow-up period was the use of statins. Many
reports have suggested that LDL-C-lowering by statins can
reduce the incidence of MACE [2e6]. In addition, the
Table 3 Medications used during treatment.
Medication Low-density lipoprotein cholesterol p
>2.94 mmol/L 2.94 mmol/L
In hospital
Aspirin 492/501 (98.2) 558/575 (97.0) 0.22
Clopidogrel 438/501 (87.4) 506/575 (88) 0.77
Statins 485/501 (96.8) 555/575 (96.5) 0.8
ACEI/ARB 372/501 (74.3) 413/575 (71.8) 0.37
Beta blockers 384/501 (76.6) 401/575 (69.7) 0.01
Glycoprotein IIb/IIIa inhibitors 46/501 (9.2) 74/575 (12.9) 0.06
Low-molecular-weight heparin 478/501 (95.4) 545/575 (94.8) 0.64
At 1-mo follow-up
Aspirin 438/494 (88.7) 496/566 (87.6) 0.61
Clopidogrel 328/494 (66.4) 364/566 (64.3) 0.48
Statins 429/494 (86.8) 453/566 (80.0) 0.003
ACEI/ARB 271/494 (54.9) 306/566 (45.9) 0.80
Beta blockers 303/494 (61.3) 315/566 (55.7) 0.06
At 6-mo follow-up
Aspirin 399/489 (81.6) 432/558 (77.4) 0.10
Clopidogrel 250/489 (51.1) 280/558 (50.2) 0.76
Statins 350/489 (71.6) 348/558 (62.4) 0.002
ACEI/ARB 220/489 (45.0) 252/558 (45.2) 0.96
Beta blockers 254/489 (51.9) 271/558 (48.6) 0.28
At 1-y follow-up
Aspirin 380/484 (78.5) 425/552 (77.0) 0.56
Clopidogrel 210/484 (43.4) 246/552 (44.6) 0.70
Statins 328/484 (67.8) 338/552 (61.2) 0.03
ACEI/ARB 203/484 (41.9) 233/552 (42.2) 0.93
Beta blockers (%) 241/484 (49.8) 263/552 (47.6) 0.49
ACEI Z angiotensin-converting enzyme inhibitor; ARB Z angiotensin receptor blocker.
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studies showed regression of atherosclerotic plaques after
a reduction in LDL-C with statins. The regression of
atherosclerosis was associated with a marked reduction in
the incidence of MACE [24]. In those studies, statins might
have provided the maximal benefit of lowering lipid levels
with long-term treatment. In the acute phase of ASTEMI,
the lipid level may not be the most important factor
influencing this process, and inflammation may be domi-
nant. Many recent studies have shown that short-term
treatment with statins has beneficial pleiotropic cardio-
vascular effects that are independent of their lipid-
lowering effects [25,26]. These effects include anti-
platelet and anti-inflammatory activities [27], protection
of the endothelium [28], dilation of coronary microvessels
[29], reduction of thrombogenesis [30], and significant
lowering of intercellular adhesion molecule-1 and E-selec-
tin levels [31]. In the present study, the rate of statin use
was significantly higher in the high LDL-C group. Although
LDL-C levels during follow-up were not available, the lower
incidence of MACE at 1-month follow-up in the high LDL-C
group may be related to the pleiotropic cardiovascular
effects of statins, independent of their lipid-lowering
effects. At 6-month and 1-year follow-up, statin use was
still significantly higher in the high LDL-C group, but the
incidence of MACE was not significantly different between
the groups. After the acute phase of ASTEMI, plaquesbecome more stable and the major function of statins may
be to lower lipid levels. LDL-C-lowering by statins can
reduce the incidence of MACE; thus, a reduction in LDL-C is
likely to reduce MACE. This could be a rational explanation
for the lack of significant difference in MACE incidence at 6-
month and 1-year follow-up between the groups.
The prevalence of risk factors (high BMI, diabetes) was
significantly higher in the high than in the low LDL-C group.
A Cox proportional hazard model analysis revealed that the
incidence of MACE after ASTEMI was not associated with
age, gender, BMI, or diabetes, but was significantly corre-
lated with hypertension, current smoking, HDL-C, beta
blocker use in hospital, and statin use. Higher HDL-C levels,
greater beta-blocker use in hospital, and statin use may
have reduced the incidence of MACE in the high LDL-C
group. Matsumoto et al. found that the LDL-C/HDL-C ratio
had an impact on outcome in patients undergoing PCI, and
that levels of HDL-C and LDL-C appeared to be equally
important in secondary prevention [20].
There are some limitations in the present study.
Informed consent was required for 1-year follow-up on
MACE and medications; therefore, LDL-C levels during
follow-up and statin doses were not available for both
groups. Data on the inflammation marker high-sensitivity C-
reactive protein (Hs-CRP) were missing; since many hospital
laboratories cannot measure Hs-CRP, it was not analyzed. In
addition, since treatment methods differed among
Table 4 MACE incidence in hospital and during 1-year follow-up.
Low-density lipoprotein cholesterol p
>2.94 mmol/L 2.94 mmol/L
In hospital
Cardiovascular death 29/501 (5.8) 40/575 (7.0) 0.44
Nonfatal myocardial infarction 1/501 (0.2) 3/575 (0.5) 0.63
Revascularization 2/501 (0.4) 2/575 (0.4) 0.99
Stroke 1/501 (0.2) 1/575 (0.2) 0.99
MACE 33/501 (6.6) 46/575 (8.0) 0.38
At 1-mo follow-up
Cardiovascular death 34/494 (6.9) 51/566 (9.0) 0.20
Nonfatal myocardial infarction 2/494 (0.4) 7/566 (1.2) 0.19
Revascularization 3/494 (0.6) 8/566 (1.4) 0.20
Stroke 1/494 (0.2) 2/566 (0.4) 1.00
MACE 40/494 (8.1) 68/566 (12.0) 0.04
At 6-mo follow-up
Cardiovascular death 40/489 (8.2) 57/558 (10.2) 0.26
Nonfatal myocardial infarction 3/489 (0.6) 9/558 (1.6) 0.13
Revascularization 24/489 (4.9) 22/558 (3.9) 0.45
Stroke 3/489 (0.6) 5/558 (0.9) 0.73
MACE 70/489 (14.3) 93/558 (16.7) 0.30
At 1-y follow-up
Cardiovascular death 56/484 (11.6) 72/552 (13.0) 0.47
Nonfatal myocardial infarction 8/484 (1.7) 16/552 (2.9) 0.18
Revascularization 55/484 (11.4) 62/552 (11.2) 0.95
Stroke 5/484 (1.0) 11/552 (2.0) 0.21
MACE 124/484 (25.6) 161/552 (29.2) 0.20
Data are presented as n (%).
MACE Z major adverse cardiovascular event (cardiovascular death, non-fatal myocardial infarction, revascularization, and stroke).
Table 5 Univariate analysis for prediction of 1-year major
adverse cardiovascular event.
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affect the incidence of MACE. Furthermore, the sample in
our study was small, so larger-scale trials are needed to
confirm the results.
In spite of this, the finding that low LDL-C on admission
was associated with poorer short-term outcome in ASTEMI is
very salient. Patients with low LDL-C may also need
aggressive risk modification with statins. The result
suggests that it is equally important that clinicians take into4003002001000
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Figure 1. Survival curves for the two groups.consideration low LDL-C as well as high LDL-C in patients
admitted with ASTEMI.
In summary, the LDL-C level on hospitalization in
patients with ASTEMI had no significant effect on the 6-
month and 1-year incidence of MACE. However, at 1-monthHazard
ratio
95% confidence
interval
p
Age 1.068 1.051e1.086 <0.001
Gender 1.758 1.231e2.511 0.002
Body mass index 1.033 0.984e1.084 0.196
Diabetes 1.578 1.062e2.344 0.024
Hypertension 1.449 1.023e2.05 0.037
Current smoker 2.858 1.899e4.302 <0.001
Low-density
lipoprotein cholesterol
0.905 0.743e1.103 0.322
High-density
lipoprotein cholesterol
0.376 0.219e0.647 <0.001
Total cholesterol 0.967 0.829e1.129 0.673
Triglyceride 0.868 0.74e1.017 0.08
Beta blocker
use in hospital
0.564 0.395e0.806 0.002
Statin use during
follow-up
0.562 0.397e0.793 0.001
Table 6 Multiple Cox proportional hazard analysis.
Hazard ratio 95% confidence interval p
Age 0.907 0.601e1.369 0.642
Gender 1.014 0.998e1.030 0.084
Diabetes 1.458 0.836e2.541 0.184
Hypertension 1.517 1.061e2.170 0.022
Current smoker 2.440 1.599e3.725 <0.001
High-density lipoprotein cholesterol 0.306 0.173e0.541 <0.001
Beta blocker use in hospitals 0.66 0.457e0.955 0.027
Statin use 0.602 0.423e0.856 0.005
212 Y.-J. Sun et al.follow-up, the incidence of MACE in the low LDL-C group
was markedly higher than in the high LDL-C group. The
analysis indicates that the LDL-C level on admission in
patients with ASTEMI is not an independent predictor of
MACE. It would be relevant to further investigate HDL-C
level on admission, beta-blocker use in hospitals, and statin
use during follow-up in relation to MACE. These findings
suggest that in the early stage of ASTEMI, all patients may
benefit from statin treatment, regardless of their LDL-C
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